Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sleepwalking and Sleep Talking01:17

Sleepwalking and Sleep Talking

Somnambulism, commonly known as sleepwalking, involves individuals engaging in activities ranging from simple walking to more complex behaviors such as driving. Sleepwalking typically occurs during the slow-wave sleep stages 3 and 4 early in the night when the person is not dreaming, contradicting the myth that sleepwalkers are acting out their dreams.
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A narrative review of drugs targeting inflammation in vascular disease.

Postgraduate medicine·2025
Same author

Theophylline for the management of respiratory disorders in adults in the 21st century: A scoping review from the American College of Clinical Pharmacy Pulmonary Practice and Research Network.

Pharmacotherapy·2023
Same author

Comparative antiplatelet effects of chlorthalidone and hydrochlorothiazide.

Journal of clinical hypertension (Greenwich, Conn.)·2022
Same author

Feasibility and preliminary efficacy for morning bright light therapy to improve sleep and plasma biomarkers in US Veterans with TBI. A prospective, open-label, single-arm trial.

PloS one·2022
Same author

Initiation of Noninvasive Ventilation for Sleep Related Hypoventilation Disorders: Advanced Modes and Devices.

Chest·2017
Same author

Definition of a COPD self-management intervention: International Expert Group consensus.

The European respiratory journal·2016

Related Experiment Video

Updated: Jun 28, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Drug Interactions With Excessive Daytime Sleepiness Treatments.

Stanley V Thomas1, Mark A Malesker1,2, Daniel E Hilleman2

  • 1Division of Pulmonary, Critical Care, and Sleep Medicine, Creighton University School of Medicine, Omaha, NE, USA.

The Journal of Pharmacy Technology : Jpt : Official Publication of the Association of Pharmacy Technicians
|October 7, 2025
PubMed
Summary

Central hypersomnolence pharmacotherapy involves potential drug interactions. Clinicians must be aware of these interactions to optimize treatment and prevent adverse reactions for patients with excessive daytime sleepiness.

Keywords:
amphetaminesarmodafinilcentral hypersomnolenceclarithromycindrug interactionslithiummethylphenidatemodafinilpitolisantsodium oxybatesolriamfetol

More Related Videos

Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments
08:36

Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments

Published on: August 8, 2019

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Related Experiment Videos

Last Updated: Jun 28, 2026

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments
08:36

Collecting Sleep, Circadian, Fatigue, and Performance Data in Complex Operational Environments

Published on: August 8, 2019

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Area of Science:

  • Pharmacology
  • Neurology
  • Clinical Pharmacy

Background:

  • Central hypersomnolence is a sleep disorder characterized by excessive daytime sleepiness.
  • Pharmacological treatments are available but carry risks of drug interactions.
  • Understanding these interactions is crucial for patient safety and treatment efficacy.

Purpose of the Study:

  • To systematically evaluate potential drug interactions associated with central hypersomnolence pharmacotherapies.
  • To identify specific medications commonly used for excessive daytime sleepiness that may interact.
  • To synthesize available data on pharmacokinetic and pharmacodynamic interactions.

Main Methods:

  • A comprehensive literature search was conducted from 1980 to June 2025 using PubMed, Scopus, and EMBASE.
  • MeSH terms included specific medications and "drug interactions"; DAILYMED was also consulted.
  • Human studies published in English, including case reports, clinical trials, reviews, guidelines, and package labeling, were selected.

Main Results:

  • Pharmacotherapy for central hypersomnolence is subject to both pharmacokinetic and pharmacodynamic drug interactions.
  • While some interactions are clinically significant, much data originates from package labeling rather than primary literature.
  • Specific medications evaluated include modafinil, armodafinil, pitolisant, sodium oxybate, and others.

Conclusions:

  • Available evidence suggests clinically significant drug interactions can occur with central hypersomnolence treatments.
  • These interactions may lead to adverse reactions, necessitating careful management.
  • Clinicians should proactively assess and minimize drug interaction risks to optimize patient pharmacotherapy.